Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

By Scagnolari Carolina   Duda Petra   Bagnato Francesca   Vito Gabriella   Alberelli Alessia   Lavolpe Vito   Girardi Enrico   Durastanti Valentina   Trojano Maria   Kappos Ludwig   Antonelli Guido  

Journal of Neurology, Vol. 254, Iss. 5, 2007-05 ,pp. : 597-604

Springer Publishing Company

Access to resources Recommend Favorite

Differential response to treatment of relapsing–remitting multiple sclerosis with IFN-&bgr;: is there a dichotomy into T-helper-1 and -17 driven disease?

By Weissert Robert  

Future Neurology, Vol. 5, Iss. 4, 2010-07 ,pp. : 481-484

Future Medicine

Access to resources Recommend Favorite

Suppression of Autoimmune Neuritis in IFN- Receptor-Deficient Mice

By Zhu Y.   Ljunggren H.-G.   Mix E.   Li H.-L.   van der Meide P.   Elhassan A.M.   Winblad B.   Zhu J.  

Experimental Neurology, Vol. 169, Iss. 2, 2001-06 ,pp. : 472-478

Elsevier

Access to resources Recommend Favorite

Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis

By Bartoš Aleš   Fialová Lenka   Soukupová Jiřina   Kukal Jaromír   Malbohan Ivan   Piťha Jiří  

Journal of Neurology, Vol. 254, Iss. 1, 2007-01 ,pp. : 20-25

Springer Publishing Company

Access to resources Recommend Favorite

Targeting leukocyte MMPs and transmigration Minocycline as a potential therapy for multiple sclerosis

By Brundula V.  

Brain, Vol. 125, Iss. 6, 2002-06 ,pp. : 1297-1308

Oxford University Press

Access to resources Recommend Favorite